NuCana Plc (NASDAQ:NCNA) shares are trading higher Wednesday after the company was granted a U.S. Patent for phosphoramidate derivatives for use in the treatment of cancer.
The Details:
U.S. Patent #11925658 was granted on Tuesday for “phosphoramidate derivatives for use in the treatment of cancer; especially in the treatment where the patient shows resistance."
NuCana shares are climbing on heavy trading volume Wednesday. According to data from Benzinga Pro, more than 49 million shares have already been traded in the session, compared to the stock’s 100-day average of only 438,327 shares.
Related News: What’s Going On With ‘Bitcoin ...